Equity Research, Broker Reports, and media content on VISTIN PHARMA AS

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about VISTIN PHARMA AS
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
Login

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on VISTIN PHARMA AS. We currently have 0 research reports from 0 professional analysts.

Open
N/A
Volume
N/A
Range Today
N/A
52 Week
0.00/0.00
Market Cap
0m
Enterprise Value
n/am
Pension Liability
# Shares
0m
Latest PE (hist)
Div Yield

Latest News/RNS

(more news)
Date Source Announcement
25Oct18 06:00 GNW Vistin Pharma ASA : 11 per cent revenue growth in third quarter 2018
02Oct18 11:28 GNW Vistin Pharma ASA : Prospectus Summary for transfer of listing from Oslo Axess to Oslo Børs
30Aug18 06:00 GNW Vistin Pharma ASA : 20 per cent revenue growth in second quarter 2018
26Apr18 06:01 GNW Vistin Pharma ASA : Delivers 22% revenue growth in first quarter 2018
22Mar18 15:36 GNW Vistin Pharma ASA : UPDATE ON THE ENERGY TRADING BUSINESS
16Mar18 09:47 GNW Vistin Pharma ASA : Torbjørn Kjus joins Vistin to develop new business area
27Feb18 06:00 GNW Vistin Pharma ASA : Fourth quarter 2017 results
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    VISTIN PHARMA AS

  • Providers covering

    VISTIN PHARMA AS

  • 14 Jan 19

Opportunity knocks

We are introducing our Best Ideas for 2019 and also review the performance of last year’s picks. We suggest ten solidly financed stocks with good business dynamics that ought to be considered for core portfolio holdings and six UK domestically focused stocks that our analysts believe should perform strongly in the event that uncertainties unwind. We also introduce a new style of research from N+1 Singer which presents a Company’s dynamics and metrics in a clear and concise manner and concentrates on the pivotal issues affecting that Company and an investment decision.

Companies: BCA CLIN CLG CBP DNLM EAH FDL FCRM FUTR GTLY INS GLE NICL SDL SPR TRI

  • 17 Jan 19

Small Cap Feast

Circassia Pharma (CIR.L) - specialty pharmaceutical company focused on respiratory disease transferring from the Main Market. No funds being raised. Due 4 Feb. Greenfields Petroleum (TSX-V:GNF) production focused company with operated assets in Azerbaijan seeking AIM dual listing including $60m private placement. Mkt cap $12.6m CAD. Expected late January 2019.

Companies: ORCP IOF FOX TEG XLM TAP FST SNG ARE SRB

  • 15 Jan 19

Share & share alike

It may only be a fortnight into the new year but many of the factors that unnerved the market last month have continued to impact sentiment. The outcome of trade talks between the US and China, concerns about global economic growth and some poor trading statements, especially in the retail sector, have all featured. Above all, Brexit and the progress of the Withdrawal Bill have dominated with the latest “high noon” due later. Despite this, we have seen a good rally in the junior markets year to date. In Share News & Views we comment on Bloomsbury, DeepMatter*, James Fisher and Helios*.

Companies: AOR APC BONH BMS CTG CRPR DMTR ESC EUSP FDM FA/ LSAI NKTN PCF SNX TCN W7L

  • 11 Jan 19

THE MONTHLY January 2019

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. 2018 was a difficult year; however, the index still outperformed its comparative London indices, falling 10.0% to 393.2, compared with -13.0% and - 18.2% for the Allshare index and the AIM index, respectively. Furthermore, several (17) companies in our index increased their capital base – 15 of our 50 constituents raised new funds, two issued shares as part consideration for acquisitions, and two had share buybacks – all factors that influence the performance of the index. Even allowing for both capital increases and share buybacks, the 12.5% fall in the index still represented a modest outperformance compared with the decline in the Allshare index. With active industry consolidation, shareholder returns remain attractive.

Companies: OPM AVO AGY APH ARBB AVCT BUR CLIG DNL DPP GTLY GDR HAYD KOOV MCL MUR NSF OXB PCA PHP REDX SCE SIXH TRX TON VAL VTA

  • 15 Jan 19

Share & share alike

It may only be a fortnight into the new year but many of the factors that unnerved the market last month have continued to impact sentiment. The outcome of trade talks between the US and China, concerns about global economic growth and some poor trading statements, especially in the retail sector, have all featured. Above all, Brexit and the progress of the Withdrawal Bill have dominated with the latest “high noon” due later. Despite this, we have seen a good rally in the junior markets year to date. In Share News & Views we comment on Bloomsbury, DeepMatter*, James Fisher and Helios*.

Companies: AOR APC BONH BMS CTG CRPR DMTR ESC EUSP FDM FA/ LSAI NKTN PCF SNX TCN W7L

  • 16 Jan 19

Trading update – strong rebound

The six-month trading update to 31 December 2018 demonstrates stronger-than-expected growth, with revenues rising 10.6% to £46.7m (c.11% at constant exchange rates (CER)). This led to a c.60% increase in cashflows before financing (+c.£5.9m) with cash balances at 31 December of £31.6m that included £10.2m from July’s placing. The stock trades at a c.65% discount to its peer group in terms of EV/Sales as the market anxiously awaits the Phase III PQ Birch data, due in Q1 2019. We leave our forecasts unchanged for FY 2019 at this point and reiterate our 47p target price.

Companies: Allergy Therapeutics
  • 16 Jan 19

Cenkos: Creo Medical Group Plc - Significant treatment milestone

Creo Medical has announced the successful treatment of its first patients in the US. Following training over the weekend, two US surgeons each performed a procedure using Creo's Speedboat device, one in the upper and one in the lower gastrointestinal tract. This is clearly a significant milestone for Creo Medical given the size and growth potential of the US market. The US treatments follow previous announcements of procedures performed in Europe, South Africa and the UK. We maintain our Buy recommendation.

Companies: Creo Medical Group
  • 18 Dec 18

Interims – strong H1, characterised by record cashflows

Interim results to 31 October provide a solid foundation for FY 2019, with revenues rising 23% (12% attributed to acquisitions) and adjusted pre-tax profit up 32% to £1.5m, benefiting from the leverage afforded by higher-margin Atik and Sentek growth. The results were characterised by strong free cashflow, rising 117% to £1.15m (+£0.6m) more than funding the EPS-accretive (7%) Fistreem acquisition during the period. With management having indicated that it hopes to acquire at least one other company before the financial year-end, the potential for upgrades is likely. We reiterate our target price of 44p, which implies a CY 2019 EV/EBITDA of 10x, adjusted P/E of 17.9x and FCF yield of 5.4%, mindful also of the prospect of further acquisitions and stronger than currently forecast trading.

Companies: Scientific Digital Imaging
  • 23 Oct 18

Quarterly Research Outlook

The June IPO of Knights Group Holdings, a Top-100 regional law firm, marked the fifth entrant to the burgeoning UK-listed legal sector. Following recent expansion of our coverage across all five listed legal firms, complemented by coverage of three broader support services peers with exposure to the sector, we revisit and build upon our views on this rapidly evolving sector.

Companies: ARS GTLY GENL KEYS KGH MNO RBGP TWD 7DIG ABBY AMS AMER ANX ARS ATYM AVON BLVN PIER CGS CAML CALL CSRT TIDE DTG DEMG ELM EMR FPM FPO FST GTLY GENL GRI GEEC HDY HMI HAYD HEAD HILS HTG HUR IBPO IOG INDI JHD JOG KEYS KGH LAM MACF MNO MKLW NAH OXIG PCA PARK CAKE PDG RBW RMM REDD RSW RNO RKH RBGP ROR SUS SCPA SHG SOLG TWD TRAK TRI VNET VTC ZTF

  • 15 Jan 19

Picking up the pace

MaxCyte saw strong progress on all fronts in H218. There was a marked acceleration in revenues and in new cell therapy licenses, and the first patient was treated with MaxCyte’s wholly-owned CARMA therapy. Sales growth in FY18 was c19% compared to 14% in FY17 following an increase in revenues of c25% in H218. The number of licensed cell therapy programmes has risen by c15 to >70 over the last six months; and commercial licensing agreements were signed with two companies. On top of this, MaxCyte advanced its first CARMA therapy into the clinic; promising results from this trial could lead to the CARMA platform becoming the main value driver for MaxCyte. We have increased our valuation by 11p/share to 358p/share.

Companies: MaxCyte
  • 04 Dec 18

Horlicks out, oncology in

GSK made two major announcements on 3 December 2018. It has finally found a buyer for its nutrition drinks business. Unilever will be buying its Horlicks and other health food drinks brands in over 20 markets for £3.1bn. This announcement was followed by the acquisition of cancer specialist, Tesaro, for £4bn ($5bn) in cash. The deal with Unilever will be executed in three parts: GSK India, the Indian consumer health arm of GSK will be merged with the Indian arm of Unilever, HUL, and GSK will get a 5.7% stake in the combined entity. This overall deal is valued at £2.6bn. The deal is likely to be completed by 2019, post which GSK can start monetising its stake in tranches. GSK will be selling its 82% stake in the Bangladesh unit for £150m in cash. The deal also involves the sale of brand rights and consumer healthcare nutrition activities in other countries for £416m in cash. In addition to the above terms, the two companies will also enter into a five-year distribution agreement with GSK’s OTC business in India. Under this agreement, HUL will market these OTC brands, which mainly include Crocin, Eno, Iodex, and Sensodyne. Tesaro’s £4bn-acquisition (acquisition price of $75 per share) represents a premium of over 60% above Tesaro’s share price on Friday, 30 November 2018. Tesaro currently markets a cancer drug, Zejula (niraparib), which was approved in March 2017 to treat adult patients with recurrent ovarian cancer. As a reminder, Tesaro was also reported to be of interest to Sanofi, which has also been bulking up its oncology portfolio.

Companies: GlaxoSmithKline
  • 04 Jan 19

Exosome collaboration deal

The collaboration agreement with a US biopharma company is exciting, and in line with ReNeuron’s decision (first announced at the H1 stage) to re-position its exosome technology platform for potential use as a delivery vehicle for biologics and/or nucleotides for gene therapy. We are looking forward to further development updates with interest.

Companies: Reneuron Group
  • 19 Dec 18

The beginning of an end

After averting the spin-off for years, GSK has finally made up its mind about letting go of the consumer health business. It has announced a JV of its consumer health business with Pfizer’s, which had repeatedly failed in securing a buyer for its consumer health business for quarters. The deal, expected to close in H2 19, is part of the bigger plan to offload eventually the business completely. Within three years of closing the transaction, GSK will look at a separate listing of the JV in the UK, leaving with it just the pharma and the vaccines businesses. GSK will hold 68% stake in the JV, with combined sales of £9.8bn ($12.7bn). The transaction will be accretive to GSK’s non-adjusted earnings in the second full year after the closing. The transaction will involve cash costs of £0.9bn (to be funded by divestment worth £1bn) plus non-cash charges of £0.3bn and aims at cost synergies of £0.5bn by 2022 (with a target of adjusted operating margin in the ‘mid-to-high 20s’ by 2022). To pacify the investors, it has confirmed a dividend of 80p per share in 2019 as well.

Companies: GlaxoSmithKline
  • 14 Jan 19

Clear route to £100m+

A strong second half has brought trading for the full year in line with expectations and leaves the business well set for 2019. An exciting pipeline of new products should supplement an already strong organic growth outlook and could lead to material upgrades in time. We see a clear path for management to realise its ambition of building a £100m+ business over the next 3-5 years. This note looks in detail on how this can be achieved.

Companies: Surgical Innovations Group
  • 14 Jan 19

Could save 100ks of lives & £’bns globally

Amid all the BREXIT hullabaloo, it is easy to forget that the government only last week committed another £20.5bn to the NHS – aiming to save a further 500,000 lives by 2029. Central to the plan is increasing the availability of next generation imaging equipment in hospitals (eg X-ray, BDM, SPECT, CT & MRI) in order to accelerate the diagnosis & treatment of serious illnesses (eg cancer, heart disease, dementia & osteoporosis).

Companies: Kromek Group